A Study to Evaluate the Effect of Povorcitinib on the QT/QTc Interval in Healthy Participants

Part of paid clinical trials in Tempe, Arizona.

Sponsor
Incyte Corporation
Study ID
NCT06441318
Phase
PHASE1
Status
Completed

Conditions

  • Healthy Participants

Eligibility Criteria

Sex
ALL
Age
18 Years - 55 Years
Healthy Volunteers
Accepted

Interventions

  • Povorcitinib — DRUG
    Povorcitinib will be administered at protocol defined dose.
  • Placebo — DRUG
    Placebo will be administered at protocol defined dose.
  • Moxifloxacin — DRUG
    Moxifloxacin will be administered at protocol defined dose.

Study Details

The purpose of this study is to evaluate the effect of povorcitinib on the QT/QTc Interval in healthy participants.

Key Dates

Start date
Jul 12, 2024
Status verified
Sep 2024
Primary completion
Sep 10, 2024
Completion
Sep 10, 2024

Study Design

Enrollment
128 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Treatment Group 1
    Povorcitinib and placebo will be administered at the protocol defined doses.
  • Experimental: Treatment Group 2
    Povorcitinib will be administered at the protocol defined doses.
  • Placebo Comparator: Treatment Group 3
    Placebo will be administered at the protocol defined doses.
  • Active Comparator: Treatment Group 4
    Moxifloxacin will be administered at the protocol defined doses.

Primary Outcome Measure

Change from Baseline in QT interval corrected using Fridericia's formula (QTcF) [ Time Frame: Up to Day 3 ]

Locations (1)

FacilityCityStateZIPSite coordinators
Celerion Clinical Research UnitTempeArizona85253-

Find similar trials in Tempe, AZ

By research site
Celerion Clinical Research Unit· Tempe, AZ

Related Studies